You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Suppliers and packagers for generic pharmaceutical drug: chlorhexidine gluconate


✉ Email this page to a colleague

« Back to Dashboard


chlorhexidine gluconate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Xttrium EXIDINE chlorhexidine gluconate AEROSOL, METERED;TOPICAL 019127 NDA Xttrium Laboratories, Inc. 0116-0505-01 946 mL in 1 BOTTLE (0116-0505-01) 2006-01-01
Xttrium EXIDINE chlorhexidine gluconate AEROSOL, METERED;TOPICAL 019127 NDA Xttrium Laboratories, Inc. 0116-0505-02 946 mL in 1 BOTTLE (0116-0505-02) 2006-01-01
Xttrium EXIDINE chlorhexidine gluconate AEROSOL, METERED;TOPICAL 019127 NDA Xttrium Laboratories, Inc. 0116-1060-18 535 mL in 1 BOTTLE, PLASTIC (0116-1060-18) 2023-11-15
Xttrium EXIDINE chlorhexidine gluconate AEROSOL, METERED;TOPICAL 019127 NDA Xttrium Laboratories, Inc. 0116-1060-32 946 mL in 1 BOTTLE, PLASTIC (0116-1060-32) 2023-11-15
Xttrium EXIDINE chlorhexidine gluconate AEROSOL, METERED;TOPICAL 019127 NDA Xttrium Laboratories, Inc. 0116-1060-33 946 mL in 1 BOTTLE, PLASTIC (0116-1060-33) 2023-11-15
Sage Prods CHLORHEXIDINE GLUCONATE chlorhexidine gluconate CLOTH;TOPICAL 021669 NDA Sage Products LLC 53462-705-20 2 CLOTH in 1 PACKAGE (53462-705-20) 2006-02-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Chlorhexidine Gluconate

Last updated: July 29, 2025

Introduction

Chlorhexidine gluconate is a widely utilized antiseptic agent with applications spanning surgical scrubs, skin disinfectants, oral rinses, and wound care. Its broad antimicrobial spectrum and proven efficacy have secured its presence in hospitals, clinics, and consumer health products globally. The demand for chlorhexidine gluconate has prompted diverse manufacturing sources, making supply chain reliability critical for pharmaceutical companies, healthcare providers, and distributors.

This article explores key suppliers, manufacturing paradigms, global market distribution, and factors influencing supply stability.

Overview of Chlorhexidine Gluconate

Chlorhexidine gluconate is a cationic bisbiguanide antiseptic compound, known for its bactericidal and bacteriostatic properties. Its chemical stability and low toxicity profile contribute to its widespread pharmaceutical applications. The global market for chlorhexidine-based products is projected to grow, driven by increased infection control measures, especially during the COVID-19 pandemic, and rising awareness of oral health[1].

The production process involves complex synthesis steps, requiring high-purity raw materials, precision manufacturing, and strict quality controls, aligning with pharmaceutical standards such as USP, EP, and JP.

Major Suppliers of Chlorhexidine Gluconate

1. Global Pharmaceutical Chemical Companies

Many multinational corporations dominate the supply landscape, leveraging extensive R&D and manufacturing capacities:

  • Global Healthcare Companies:

    • Mikrogen (Germany) – Known for producing high-grade chlorhexidine gluconate solutions, Mikrogen emphasizes quality and compliance with international pharmacopeia standards.
    • Fresenius Kabi (Germany) – Supplies chlorhexidine gluconate formulations for clinical use, benefiting from a robust global distribution network.
    • Sanofi (France) – Engages in the synthesis and distribution of chlorhexidine preparations, particularly in oral health products.
  • Asian Chemical Producers:

    • Jiangsu Yueyang Pharmaceutical (China) – Manufactures chlorhexidine gluconate powder and solutions, catering to both domestic and export markets.
    • Hubei Jumpcan Pharmaceutical (China) – Focuses on high-quality chlorhexidine gluconate for medical disinfectants.
    • Shandong Luoxin Pharmaceutical Group (China) – Offers a range of antiseptic agents, including chlorhexidine gluconate.

2. Contract Manufacturing and Private Label Suppliers

Several companies serve as contract manufacturers or private label producers:

  • Kent Pharmaceutical (India) – Supplies chlorhexidine gluconate-based products under private labels, emphasizing affordability and volume.
  • Sino Pharm (China) – Provides contract manufacturing services with ISO-certified facilities for chlorhexidine compounds.

3. Raw Material and Precursors

Suppliers of essential raw materials impact overall availability:

  • Mitsubishi Chemical (Japan) – Provides raw chemicals critical for the synthesis process.
  • BASF (Germany) – Supplies key intermediates used in chlorhexidine gluconate production.

4. Distributors and Marketplaces

Distributors play a crucial role in bridging manufacturing and end-use markets:

  • Alibaba and Global Sources – Offer marketplaces connecting buyers with Chinese and Indian manufacturers.
  • Medline Industries (USA) – Distributes chlorhexidine-based surgical scrubs and skin disinfectants.

Key Market Dynamics and Factors Influencing Supply

a. Manufacturing Standards and Certifications

Suppliers adhering to stringent regulatory standards (e.g., ISO 13485, cGMP, WHO GMP) ensure product consistency and regulatory approval. The complexity of synthesis requires suppliers to maintain rigorous quality controls, influencing supply reliability.

b. Raw Material Availability

Supply depends on raw material availability, notably chlorhexidine base and gluconic acid precursors. Fluctuations in raw material prices or disruptions can impact manufacturing output.

c. Geopolitical and Trade Factors

Trade restrictions, tariffs, and geopolitical tensions—especially involving China and India, key manufacturing hubs—can affect supply continuity. The COVID-19 pandemic underscored vulnerabilities in global supply chains, prompting diversification strategies among buyers.

d. Regulatory and Quality Compliance

Stringent regulatory requirements in developed markets necessitate continuous compliance, certification, and frequent audits, which can influence manufacturer capacity and output stability.

e. Innovation and Patent Landscapes

While chlorhexidine gluconate is generally off-patent, formulations and delivery mechanisms might be covered by patents. Suppliers innovating with formulation enhancements may secure competitive advantages.

Regional Supply Insights

  • Asia-Pacific: Dominates global manufacturing capacity due to cost advantages and large-scale chemical production. Chinese and Indian manufacturers supply significant volumes, often catering to both domestic and international markets.

  • Europe: Focuses on high-quality, GMP-compliant products for clinical and pharmaceutical use, serving strict regulatory markets such as the US and Europe.

  • North America: Major importers and distributors, with some domestic manufacturing centers primarily involved in formulation rather than synthesis.

Supply Chain Challenges and Opportunities

Challenges:

  • Raw material shortages
  • Regulatory delays and compliance costs
  • Geopolitical disruptions
  • Variability in manufacturing quality

Opportunities:

  • Diversifying manufacturing sources
  • Implementing strategic stockpiles
  • Investing in regulatory harmonization
  • Developing formulations with improved stability

Conclusion

A resilient supply chain for chlorhexidine gluconate hinges on diversified sourcing, strict adherence to quality standards, and proactive risk management. Major suppliers span Europe, North America, and Asia, with China and India serving as primary manufacturing hubs. Buyers should develop strategic partnerships with certified suppliers, ensure traceability, and maintain familiarity with geopolitical developments influencing supply stability.


Key Takeaways

  • The global supply of chlorhexidine gluconate is primarily driven by manufacturers in Asia (China and India) and Europe, with North American imports fulfilling demand.
  • Quality compliance, including cGMP and pharmacopeial standards, remains critical for supply dependability.
  • Raw material availability and geopolitical factors are significant determinants of supply stability.
  • Diversification in supplier networks and regional sources mitigates risks associated with reliance on single-source providers.
  • Staying ahead of regulatory developments and fostering innovation can bolster supply resilience and market competitiveness.

FAQs

1. Who are the leading manufacturers of chlorhexidine gluconate globally?
Major players include Mikrogen (Germany), Fresenius Kabi (Germany), Jiangsu Yueyang Pharmaceutical (China), and Hubei Jumpcan Pharmaceutical (China), among others.

2. What factors influence the global supply chain of chlorhexidine gluconate?
Key factors include manufacturing standards, raw material availability, geopolitical stability, regulatory compliance, and manufacturing capacity.

3. Are there any significant raw material suppliers for chlorhexidine gluconate?
Yes, companies like Mitsubishi Chemical (Japan) and BASF (Germany) supply essential chemical precursors critical for synthesis.

4. How does regional distribution impact supply reliability?
Asia-Pacific dominates manufacturing, while Europe and North America focus on quality and regulatory compliance, leading to a geographically dispersed supply chain that can mitigate localized disruptions.

5. What should companies consider when sourcing chlorhexidine gluconate?
They should prioritize suppliers with certified quality standards, ensure raw material traceability, assess geopolitical and regulatory stability, and consider diversifying sources to ensure supply continuity.


References

  1. MarketsandMarkets. "Chlorhexidine Market by Application, Formulation, and Region - Global Forecast to 2028."

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.